Merck KGaA (MKGAF) reports robust Q4 results with significant growth across sectors, despite challenges in Life Science and ...

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...

Reports Q4 revenue $42.8M, consensus $39.03M. “We achieved significant revenue growth in 2024 driven by strong momentum across our major ...